Trial profile for the pharmacokinetics and pharmacodynamics study in patients with dyslipidaemia (A) and the ambulatory blood pressure study (B) *Participants.

Slides:

Advertisements

Similar presentations

Montalescot G, et al. Lancet 2009;373: Trial profile Montalescot G, et al. Lancet 2009;373:

Advertisements

Weng TC, et al. J Clin Pharm Ther 2010;35:

The Indian Polycap Study (TIPS). Lancet 2009 Mar 30 [Epub]

Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:

Efficacy and Comparability of Thiazide-type Diuretics

Liraglutide Promotes Natriuresis but Does Not Increase Circulating Levels of Atrial Natriuretic Peptide in Hypertensive Subjects With Type 2 Diabetes Featured.

Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension Featured Article: Ilkka Tikkanen, Kirsi Narko, Cordula Zeller, Alexandra.

Ridker PM, et al. Lancet 2009;373: Baseline clinical characteristics of the study population in the placebo and rosuvastatin groups according.

Study design: a randomized placebo- controlled crossover trial of 2 periods of 4 weeks Nicole A.J. van der Linde, et al. Hypertension 2006;47;

Baseline characteristics of HPS participants by prior cerebrovascular disease.

Powered by Infomedica Infomedica Conference Coverage* of 26 th European Meeting on Hypertension and Cardiovascular Protection Paris (France), June 10-13,

Yale Mitchel, MD Cardiovascular Disease Department

Blood Pressure and Lipid Trials: Rationale, Importance and Design

Raw data Log-transformed data Male age log age Female age log age

Trial profile SAS denotes the Simvastatin in Aortic Stenosis Study

Rates of Ambulatory Care Visits for Treating Adverse Drug Events (VADEs): Trend 1995–2001 Data: National Ambulatory Medical Care Survey and National Hospital.

Kidney Blood Press Res 2013;37: DOI: /

All-cause mortality by treatment group

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial Randomized, double-blind, placebo-controlled cardiovascular.

Neal B, et al. Diabetes Care 2015;38:403–411

REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Louise Bowman on behalf of the HPS.

Effects of Anacetrapib on the Incidence of New-Onset Diabetes Mellitus and on Vascular Events in People With Diabetes Louise Bowman & Martin Landray on.

HbA1c 1245_0025final study-report-body. Table : 1 HbA1c (%) change from baseline MMRM results over time − FAS (OC−AD)

Mean 24-Hour, Daytime, and Night Ambulatory Systolic BP, Diastolic BP, and PP Before (Week 0) and After (Week 12) NAG and Placebo Intake in 37 Hypertensive.

Volume 376, Issue 9734, Pages (July 2010)

Comparison of baseline characteristics in participants who subsequently had an incident cardiovascular event or new-onset diabetes in the Prospective.

Copyright © 2012 American Medical Association. All rights reserved.

Relative mortality risk associated with quartiles of systolic blood pressure compared with systolic

Volume 386, Issue 10008, Pages (November 2015)

Cholesterol and blood pressure values at baseline and after 15 days of dark-chocolate and white-chocolate consumption Characteristic Dark chocolate before.

Krzysztof Narkiewicz et al. BTS 2016;1:

The Hypertension in the Very Elderly Trial (HYVET)

Volume 376, Issue 9734, Pages (July 2010)

Trial profile John A Dormandy et al. Lancet 2005;366:

Why double blind, controlled randomized trials?

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

Relative risk of major events with atenolol vs placebo

Becker RC, et al. Lancet 2009;373:919-28

A: Kaplan-Meier estimate of time to first LLA

Description of studies for pooled analyses

Volume 88, Issue 2, Pages (August 2015)

Efficacy and safety of niacin/laropiprant

PATHWAY-2: spironolactone for resistant hypertension – Authors' reply

ACCELERATE Trial design: Patients at high vascular risk were randomized to either evacetrapib 130 mg daily or placebo. They were followed for 30 months.

Volume 386, Issue 10008, Pages (November 2015)

POPE-2 Trial design: Patients with moderate to large pericardial effusion after cardiac surgery were randomized to colchicine 2 mg loading dose, then 1.

Trial profile Luc F Van Gaal, Lancet 2005;365:1389.

Flow of Patients Through Trial

Baseline Characteristics, Blood Pressures, and Laboratory Values

RUTHERFORD-2 Trial design: Patients with heterogeneous familial hypercholesterolemia (HeFH) on statins were randomized in a 2:2:1:1 fashion to subcutaneous.

Baseline Characteristics of the Subjects*

Baseline characteristics for patients with diabetes in ASCOT-LLA Part I P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157.

DENERHTN Trial design: Patients with resistant hypertension were randomized to renal denervation plus standardized stepped-care antihypertensive treatment.

SOLID-TIMI 52 Trial design: Participants within 30 days of an acute coronary syndrome (ACS) were randomized to darapladib 160 mg daily (n = 6,504) versus.

Participation in Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Hisao Ogawa et al. JAMA 2008;300:

Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,

Patients’ most feared AEs reported to be intolerable when lasting more than 7 days at baseline, on study and at study completion (% patients); (A) grade.

Lars E. Laugsand et al. BTS 2016;j.jacbts

Change in (A) systolic blood pressure and (B) diastolic blood pressure over 5 years in response to 12-week intensive lifestyle intervention in a real-world.

PROSPER: trial design

Pramlintide Therapy Part 1of 2

Forest plot of CIMT progression rate for atorvastatin treatment versus placebo for 3 years by baseline serum 25-hydroxyvitamin D status. Forest plot of.

Percentage of patients with type 2 diabetes with A1C < 7% (n = 248), blood pressure > 130/80 mmHg (n = 248), and LDL cholesterol < 100 mg/dl (n = 207)

Baseline demographics and clinical characteristics of 3,956 rosuvastatin-treated patients Donald G. Vidt, et al. Am J Cardiol 2006;97:1602–1606.

Flow of study participants

Effect of RO and placebo on IOP

Mean adjusted levels in each group for the following cardiometabolic risk factors at 3 and 12 months postpartum: (A) systolic blood pressure, (B) diastolic.

Effects of placebo or carvedilol CR on 24-hour mean systolic blood pressure and diastolic blood pressure obtained by ambulatory monitoring in hypertensive.

PHOENIX I: PASI 75 Response After 12 Weeks

Presentation transcript:

Trial profile for the pharmacokinetics and pharmacodynamics study in patients with dyslipidaemia (A) and the ambulatory blood pressure study (B) *Participants who received drug in period 1 received placebo in period 2 and vice versa Rajesh Krishna, et al. Lancet 2007;370:1907-14

Change from baseline versus time profiles for serum HDL-C (A), LDL-C (B), apolipoprotein A-I (C), and apolipoprotein B (D) after administration of anacetrapib or placebo to patients with dyslipidaemia Rajesh Krishna, et al. Lancet 2007;370:1907-14

Hourly mean systolic (A) and diastolic (B) blood pressure (SE) over 24 h post-dose on day 10 after administration of anacetrapib (or matching placebo) in healthy middle-aged and elderly people (N=22) R. Krishna, et al. Lancet 2007;370:1907-14

Mean ambulatory systolic and diastolic blood pressure at 24 h post-dose on day 10 after administration of anacetrapib or placebo in healthy middle-aged and elderly people (N=22) Rajesh Krishna, et al. Lancet 2007;370:1907-14

Incidence of adverse events in patients with dyslipidaemia Rajesh Krishna, et al. Lancet 2007;370:1907-14

Incidence of adverse events in ambulatory blood pressure study Rajesh Krishna, et al. Lancet 2007;370:1907-14